Sevenless Therapeutics ApS - CVR: 43311999

2023, DKK

26.06.2024

Bruttoresultat

-692'

Primær drift

-692'

Årets resultat

-103'

Aktiver

12.017'

Kortfristede aktiver

2.875'

Egenkapital

112'

Afkastningsgrad

-6 %

Soliditetsgrad

1 %

Likviditetsgrad

+500%

Resultat

26.06.2024

Årsrapport	2023 26.06.2024	2022 30.06.2023
Nettoomsætning
Bruttoresultat	-691.735	-141.501
Resultat af primær drift	-691.735	-141.501
Indtægter af kapitalandele (tilknyttede og associerede)	0	0
Finansielle indtægter	19.536	26.867
Finansieringsomkostninger	-10.069	-12.667
Andre finansielle omkostninger	0	0
Resultat før skat	-682.268	-127.301
Resultat	-103.456	175.394
Forslag til udbytte	0	0

Aktiver

26.06.2024

Årsrapport	2023 26.06.2024	2022 30.06.2023
Kortfristede varebeholdninger	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	1.130.571	860.141
Likvider	1.743.969	4.024.687
Kortfristede aktiver	2.874.540	4.884.828
Immaterielle aktiver og goodwill	9.142.006	3.821.860
Finansielle anlægsaktiver	0	0
Materielle aktiver	0	0
Langfristede aktiver	9.142.006	3.821.860
Aktiver	12.016.546	8.706.688

Aktiver

26.06.2024

Passiver

26.06.2024

Årsrapport	2023 26.06.2024	2022 30.06.2023
Forslag til udbytte	0	0
Egenkapital	111.937	215.394
Hensatte forpligtelser	986.835	0
Langfristet gæld til banker	0	0
Leverandører af varer og tjenesteydelser	355.642	0
Kortfristede forpligtelser	385.493	1.415.541
Gældsforpligtelser	10.917.774	8.491.294
Forpligtelser	10.917.774	8.491.294
Passiver	12.016.546	8.706.688

Passiver

26.06.2024

Nøgletal

26.06.2024

Årsrapport	2023 26.06.2024	2022 30.06.2023
Afkastningsgrad	-5,8 %	-1,6 %
Dækningsgrad	Na.	Na.
Resultatgrad	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.
Egenkapitals-forretning	-92,4 %	81,4 %
Payout-ratio	Na.	Na.
Gældsdæknings-nøgletal	-6.869,9 %	-1.117,1 %
Soliditestgrad	0,9 %	2,5 %
Likviditetsgrad	745,7 %	345,1 %

Resultat

26.06.2024

Gæld

26.06.2024

Årsrapport

26.06.2024

Nyeste:01.01.2023- 31.12.2023(offentliggjort: 26.06.2024)

Information om virksomhedens regnskabsklasse:This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises with addition of a few provisions for reporting class C.

Oplysning om pantsætninger og sikkerhedsstillelser:5. Collaterals and securities The Company has no collaterals and has not provided any securities.

Beretning

26.06.2024

Ledelsespåtegning: The Board of Directors has today considered and approved the annual report of for the financial year 1 January 2023 - 31 December 2023 for Sevenless Therapeutics ApS. The annual report, which has not been audited, is presented in accordance with the Danish Financial Statements Act. Management believes that the financial statements give a true and fair view of the company's assets, liabilities and financial position and of the result for the finacial year 2023. We believe that the management commentary contains a fair revier of the affairs and conditions referred to therein. Management considers the conditions for opting out of audit to be met. The annual report is submitted for approval by the General Assembly. Copenhagen, 26 June 2024 Management Alex Leech Neil Benson Alasdair Naylor

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:The Board of Directors has today considered and approved the annual report of for the financial year 1 January 2023 - 31 December 2023 for Sevenless Therapeutics ApS.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:The Company's principal activities Sevenless Therapeutics ApS is a private drug discovery and development company whose principal activity is to develop medicines for the treatment of diseases with high unmet medical needs.